Home    Back

Enriched hematopoetic stem cell infusion    (DrugBank: -)

3 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1
19Lysosomal storage disease2
284Diamond-Blackfan anemia1

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", ... show all
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02084121
(ClinicalTrials.gov)		March 20147/3/2014Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)Metachromatic LeukodystrophyBiological: Enriched Hematopoetic Stem Cell InfusionTalaris Therapeutics Inc.Duke UniversityNo longer available3 YearsN/AMaleUnited States

19. Lysosomal storage disease    [ 784 clinical trials,   673 drugs,   (DrugBank: 101 drugs),   68 drug target genes,   184 drug target pathways]
Searched query = "Lysosomal storage disease", "Lysosomal disease", "Gaucher disease", "Niemann-Pick disease", "Niemann-Pick type C", "GM1-gangliosidosis", "GM1-ganglio ... show all
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 784 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02084121
(ClinicalTrials.gov)		March 20147/3/2014Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)Metachromatic LeukodystrophyBiological: Enriched Hematopoetic Stem Cell InfusionTalaris Therapeutics Inc.Duke UniversityNo longer available3 YearsN/AMaleUnited States
2NCT02021266
(ClinicalTrials.gov)		April 201319/12/2013Single Patient Expanded Access Protocol: Metabolic BoostSingle Patient Expanded Access Protocol: Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic DisordersMetachromatic LeukodystrophyBiological: Enriched Hematopoetic Stem Cell InfusionTalaris Therapeutics Inc.Duke UniversityNo longer availableN/AN/AFemalePhase 1;Phase 2United States

284. Diamond-Blackfan anemia    [ 37 clinical trials,   110 drugs,   (DrugBank: 34 drugs),   22 drug target genes,   121 drug target pathways]
Searched query = "Diamond-Blackfan anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 37 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01419704
(ClinicalTrials.gov)		May 201116/8/2011Phase I/II Pilot Study of Mixed Chimerism to Treat HemoglobinopathiesPhase I/II Pilot Study of Mixed Chimerism to Treat HemoglobinopathiesAnemia, Sickle Cell;Complex and Transfusion-dependent Hemoglobinopathies;Thalassemia;Diamond-Blackfan Anemia;Bone Marrow Failure Syndromes;Alpha-Thalassemia;Beta-ThalassemiaBiological: Enriched Hematopoetic Stem Cell InfusionTalaris Therapeutics Inc.Duke UniversitySuspendedN/A45 YearsAll30Phase 1;Phase 2United States